ZA988789B - Vaccine. - Google Patents

Vaccine.

Info

Publication number
ZA988789B
ZA988789B ZA9808789A ZA988789A ZA988789B ZA 988789 B ZA988789 B ZA 988789B ZA 9808789 A ZA9808789 A ZA 9808789A ZA 988789 A ZA988789 A ZA 988789A ZA 988789 B ZA988789 B ZA 988789B
Authority
ZA
South Africa
Prior art keywords
vaccine
Prior art date
Application number
ZA9808789A
Other languages
English (en)
Inventor
Claudine Bruck
Stephane Andre Georges Godart
Martine Marchand
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA988789(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of ZA988789B publication Critical patent/ZA988789B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA9808789A 1997-09-26 1998-09-25 Vaccine. ZA988789B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine

Publications (1)

Publication Number Publication Date
ZA988789B true ZA988789B (en) 2000-03-29

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9808789A ZA988789B (en) 1997-09-26 1998-09-25 Vaccine.

Country Status (28)

Country Link
EP (1) EP1015596B2 (es)
JP (2) JP2001518300A (es)
KR (1) KR100554487B1 (es)
CN (1) CN1188519C (es)
AR (2) AR017147A1 (es)
AT (1) ATE338128T1 (es)
AU (1) AU746564B2 (es)
BR (1) BR9812547A (es)
CA (1) CA2305013C (es)
CO (1) CO4810339A1 (es)
CZ (1) CZ302878B6 (es)
DE (1) DE69835756T3 (es)
DK (1) DK1015596T4 (es)
ES (1) ES2272012T5 (es)
GB (1) GB9720585D0 (es)
HK (1) HK1030431A1 (es)
HU (1) HUP0004896A3 (es)
IL (1) IL135102A0 (es)
NO (2) NO328824B1 (es)
NZ (1) NZ503482A (es)
PL (1) PL195243B1 (es)
PT (1) PT1015596E (es)
SA (1) SA98190877B1 (es)
SI (1) SI1015596T2 (es)
TR (1) TR200000864T2 (es)
TW (1) TW499436B (es)
WO (1) WO1999016884A1 (es)
ZA (1) ZA988789B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
EP1156825A2 (en) * 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
ATE342275T1 (de) * 1999-04-12 2006-11-15 Heart Biosystems Gmbh Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
DE60023300T2 (de) * 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
OA12168A (en) * 2000-01-31 2006-05-08 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
BR0214350A (pt) 2001-11-21 2005-05-10 Univ Pennsylvania Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
UA85373C2 (ru) 2002-05-16 2009-01-26 Бавариан Нордик А/С Слитый протеин регуляторных/аксессорных hіv протеинов
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
IN2014DN06624A (es) * 2005-10-18 2015-07-10 Univ Colorado
ES2607029T3 (es) 2007-11-28 2017-03-28 The Trustees Of The University Of Pennsylvania Adenovirus que comprende una proteína hexónica de la cápside del adenovirus E de simio SAdV-39 y usos de la misma
EP2220217A2 (en) 2007-11-28 2010-08-25 The Trustees of the University of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
US8470310B2 (en) 2008-03-04 2013-06-25 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-36, -42.1, -42.2, and -44 and uses thereof
CA2723114C (en) 2008-05-16 2018-02-27 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
CN102083970B (zh) 2008-07-21 2014-10-22 泰加生物工艺学公司 分化无核细胞及其制备方法
WO2010025421A2 (en) 2008-08-28 2010-03-04 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
EP2774985B1 (en) 2008-10-31 2016-12-14 The Trustees Of The University Of Pennsylvania Simian adenovirus SAdV-43 and uses thereof
BRPI1009215B1 (pt) 2009-03-23 2019-10-29 Nanirx Inc composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer
EP2435559A1 (en) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
EP2708561A4 (en) * 2011-03-15 2014-09-24 Univ Yonsei Iacf BIO-PIN
WO2013173702A2 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
DK2877189T3 (da) 2012-07-20 2021-02-22 Taiga Biotechnologies Inc Forbedret rekonstituering og autorekonstituering af det hæmopoietiske kammer
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
CN106470736B (zh) 2014-05-13 2021-05-28 宾夕法尼亚州大学信托人 包括表达双抗体构建体的aav的组合物及其用途
JP6886406B2 (ja) * 2015-04-16 2021-06-16 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
IL281425B (en) 2016-12-02 2022-07-01 Taiga Biotechnologies Inc Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US20240226324A1 (en) 2021-04-27 2024-07-11 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
DE656950T1 (de) * 1992-08-21 1996-03-14 Biogen Inc Tat-derivate transport polypeptide.
DE69434469T2 (de) * 1993-01-26 2006-06-14 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
CA2215483C (fr) * 1995-03-08 2012-01-03 Jean-Francois Zagury Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
NZ503482A (en) 2001-09-28
CA2305013C (en) 2008-04-08
DE69835756D1 (de) 2006-10-12
NO20001508L (no) 2000-05-18
CN1188519C (zh) 2005-02-09
CZ20001091A3 (cs) 2000-09-13
SI1015596T1 (sl) 2007-02-28
ES2272012T3 (es) 2007-04-16
IL135102A0 (en) 2001-05-20
KR20010024287A (ko) 2001-03-26
HK1030431A1 (en) 2001-05-04
EP1015596A1 (en) 2000-07-05
EP1015596B1 (en) 2006-08-30
BR9812547A (pt) 2000-07-25
CO4810339A1 (es) 1999-06-30
CN1279718A (zh) 2001-01-10
NO20076467L (no) 2000-05-18
PL339432A1 (en) 2000-12-18
NO328824B1 (no) 2010-05-25
EP1015596B2 (en) 2010-04-14
TR200000864T2 (tr) 2000-08-21
HUP0004896A3 (en) 2003-05-28
JP2009213492A (ja) 2009-09-24
DE69835756T3 (de) 2010-09-30
ES2272012T5 (es) 2010-07-06
TW499436B (en) 2002-08-21
SA98190877B1 (ar) 2006-09-10
PL195243B1 (pl) 2007-08-31
AR017147A1 (es) 2001-08-22
CA2305013A1 (en) 1999-04-08
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
SI1015596T2 (sl) 2010-07-30
AU746564B2 (en) 2002-05-02
WO1999016884A1 (en) 1999-04-08
CZ302878B6 (cs) 2012-01-04
GB9720585D0 (en) 1997-11-26
JP2001518300A (ja) 2001-10-16
KR100554487B1 (ko) 2006-03-03
AR080331A2 (es) 2012-03-28
ATE338128T1 (de) 2006-09-15
AU1025599A (en) 1999-04-23
DE69835756T2 (de) 2007-09-13
HUP0004896A1 (hu) 2001-04-28
DK1015596T3 (da) 2007-01-02
DK1015596T4 (da) 2010-07-12

Similar Documents

Publication Publication Date Title
ZA9811848B (en) Vaccine.
ZA984969B (en) Vaccine.
ZA988789B (en) Vaccine.
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
GB9726555D0 (en) Vaccine
HK1016976A1 (en) Resorcinyl-triazine.
EP1083926A4 (en) VACCINE
ZA976815B (en) Vaccine composition.
ZA981926B (en) Detergent--package combination.
ZA987055B (en) Substituted 4-benzoylpyrazoles.
DE59804842D1 (en) Aliphatische, emissionsarme, sinterfähige thermoplastische polyurethanformmassen
ZA987058B (en) Substituted 4-benzoylpyrazoles.
ZA987662B (en) Neospora Vaccine.
PL344519A1 (en) Vaccine
HK1017834A1 (en) Bodyshaper.
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA987B (en) Substituted 4-benzoylpyrazoles.
ZA982763B (en) Vaccines
ZA984696B (en) Vaccine compositions V.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
ZA983795B (en) Substituted 4-benzoyl-pyrazoles.
ZA987303B (en) Vaccine.
ZA983698B (en) Estrenes.
ZA98263B (en) O-fucosyltransferase.